I agree that this site is using cookies. You can find further informations here.
X
Tamiya, Motohiro
79  results:
OpenAccess-fulltext X
Search for persons X
?
1

Radial endobronchial ultrasound with a guide sheath for dia..:

Hayama, Manabu ; Okamoto, Norio ; Suzuki, Hidekazu...
http://www.biomedcentral.com/1471-2466/16/76.  , 2016
Link: http://www.biomedcentral..
 
?
2

Comparison of the clinical courses and chemotherapy outcome..:

Hirashima, Tomonori ; Nagai, Takayuki ; Shigeoka, Hironori...
http://www.biomedcentral.com/1471-2407/14/770.  , 2014
Link: http://www.biomedcentral..
 
?
3

Real-world outcomes of nivolumab plus ipilimumab and pembro..:

Matsumoto, Kinnosuke ; Shiroyama, Takayuki ; Tamiya, Motohiro...
Cancer Immunology, Immunotherapy. 2024, 73(4).  ,
Link: https://ir.library.osaka..
 
?
4

Supplemental Table 1 from Phase II Study of the Liposomal F..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
https://figshare.com/articles/journal_contribution/Supplemental_Table_1_from_Phase_II_Study_of_the_Liposomal_Formulation_of_Eribulin_E7389-LF_in_Combination_with_Nivolumab_Results_from_the_Small_Cell_Lung_Cancer_Cohort/25103047.  , 2024
Link: https://doi.org/10.1158/..
 
?
5

Supplemental Figure 3 from Phase II Study of the Liposomal ..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
doi:10.1158/2767-9764.25103056.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
6

Supplemental Methods from Phase II Study of the Liposomal F..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
doi:10.1158/2767-9764.25103050.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
7

Supplemental Table 4 from Phase II Study of the Liposomal F..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
https://figshare.com/articles/journal_contribution/Supplemental_Table_4_from_Phase_II_Study_of_the_Liposomal_Formulation_of_Eribulin_E7389-LF_in_Combination_with_Nivolumab_Results_from_the_Small_Cell_Lung_Cancer_Cohort/25103038.  , 2024
Link: https://doi.org/10.1158/..
 
?
8

FIGURE 2 from Phase II Study of the Liposomal Formulation o..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
doi:10.1158/2767-9764.25103071.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
9

Presentation_1_Prognostic impact of clinical factors for im..:

Shota Takei ; Hayato Kawachi ; Tadaaki Yamada...
doi:10.3389/fimmu.2024.1348034.s001.  , 2024
Link: https://doi.org/10.3389/..
 
?
10

Supplemental Figure 3 from Phase II Study of the Liposomal ..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
https://figshare.com/articles/journal_contribution/Supplemental_Figure_3_from_Phase_II_Study_of_the_Liposomal_Formulation_of_Eribulin_E7389-LF_in_Combination_with_Nivolumab_Results_from_the_Small_Cell_Lung_Cancer_Cohort/25103056.  , 2024
Link: https://doi.org/10.1158/..
 
?
11

FIGURE 4 from Phase II Study of the Liposomal Formulation o..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
doi:10.1158/2767-9764.25103065.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
12

Presentation_1_Prognostic impact of clinical factors for im..:

Shota Takei ; Hayato Kawachi ; Tadaaki Yamada...
https://figshare.com/articles/presentation/Presentation_1_Prognostic_impact_of_clinical_factors_for_immune_checkpoint_inhibitor_with_or_without_chemotherapy_in_older_patients_with_non-small_cell_lung_cancer_and_PD-L1_TPS_50_pptx/25271359.  , 2024
Link: https://doi.org/10.3389/..
 
?
13

FIGURE 3 from Phase II Study of the Liposomal Formulation o..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
https://figshare.com/articles/figure/FIGURE_3_from_Phase_II_Study_of_the_Liposomal_Formulation_of_Eribulin_E7389-LF_in_Combination_with_Nivolumab_Results_from_the_Small_Cell_Lung_Cancer_Cohort/25103068.  , 2024
Link: https://doi.org/10.1158/..
 
?
14

Supplemental Table 3 from Phase II Study of the Liposomal F..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
doi:10.1158/2767-9764.25103041.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
15

Supplemental Table 2 from Phase II Study of the Liposomal F..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
doi:10.1158/2767-9764.25103044.v1.  , 2024
Link: https://doi.org/10.1158/..
 
1-15